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ABSTRACT 48 
Background. Diabetes mellitus is frequently observed in pancreatic cancer patients and is both a risk 49 
factor and an early manifestation of the disease.  50 
Methods. We analyzed the prognostic impact of diabetes on the outcome of pancreatic cancer 51 
following resection and adjuvant chemotherapy using individual patient data from three European 52 
Study Group for Pancreatic Cancer (ESPAC) randomized controlled trials.  Analyses were carried out 53 
to assess the association between clinical characteristics and the presence of pre-operative diabetes 54 
as well as the effect of diabetic status on overall survival.   55 
Results.  1105 patients were included in the analysis, of whom 257 (23%) had confirmed diabetes 56 
and 848 (77%) did not. Median (95% confidence interval) unadjusted overall survival in non-diabetic 57 
patients was 22.3 (20.8 - 24.1) months compared to 18.8 (16.9 - 22.1) months for diabetic patients 58 
(p=0.24). Diabetic patients were older, had increased weight and more co-morbidities. Following 59 
adjustment, multivariable analysis demonstrated that diabetic patients had an increased risk of 60 
death (HR: 1.19 (95%CI 1.01, 1.40), P=0.034). Maximum tumor size (MTS) of diabetic patients was 61 
larger at randomization (33.6mm vs 29.7mm, p=0.026).   62 
Conclusions. Diabetes mellitus was associated with increased tumor size and reduced survival 63 
following pancreatic cancer resection and adjuvant chemotherapy. 64 
 65 
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INTRODUCTION 70 
Pancreatic cancer is currently the fourth most common cause of cancer related mortality in 71 
developed countries (Siegel et al, 2015) and is predicted to be the second leading cause within the 72 
next decade (Rahib et al, 2014). Most patients are diagnosed at an advanced stage with distant 73 
metastasis and/or locally advanced unresectable tumors (Hidalgo et al, 2015). Together with limited 74 
and often ineffective treatment options, this results in an overall low 5-year survival rate of less than 75 
7%. Surgery, the only chance for cure, can be offered to only 15-20% of patients resulting in 76 
approximately 20% 5-year survival rates (Kleeff et al, 2016).  77 
 78 
Risk factors that have been identified for pancreatic cancer include tobacco smoking, diabetes 79 
mellitus, and others (Bosetti et al, 2012; Kleeff et al, 2016). Several studies have established that 80 
diabetes mellitus has a higher prevalence in patients with pancreatic cancer than other cancers or 81 
control subjects especially in patients with a more recent diagnosis (Aggarwal et al, 2013; Chari et al, 82 
2008; Pannala et al, 2008). Systematic reviews and meta-analyses have confirmed that diabetes is a 83 
risk factor for pancreatic cancer with risk ratios of around 1.8-2.1 (Ansary-Moghaddam et al, 2006; 84 
Ben et al, 2011; Huxley et al, 2005; Stevens et al, 2007). The risk is higher with recent onset diabetes 85 
(Ben et al, 2011; Calle et al, 1998; Huxley et al, 2005), possibly as an early manifestation of pancreatic 86 
cancer. In contrast to an earlier report (Gullo et al, 1994) long standing diabetes mellitus (> 5 years) 87 
has also been shown to have an increased risk of pancreatic cancer of 1.5-2.0 (Everhart & Wright, 88 
1995; Huxley et al, 2005; Li et al, 2011). There is still an excess risk of pancreatic cancer even with a 89 
long standing diagnosis of diabetes of 20 years or more but at a lower level with an odds ratio of 1.3 90 
(Bosetti et al, 2014). There is some evidence that diabetes mellitus may resolve after pancreatic 91 
cancer resection in a proportion of new-onset cases, whereas it remains unchanged in patients with 92 
long standing diabetes (Pannala et al, 2008; Permert et al, 1993), which appears to be specific for 93 
pancreatic cancer, as resection for chronic pancreatitis does not improve pre-existing diabetes 94 
(Litwin et al, 2008). While diabetes mellitus increases the risk of pancreatic cancer, there is also 95 
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evidence that pancreatic cancer itself induces diabetes (type 3c). Potential mechanisms include the 98 
release of adrenomedullin, a potential mediator of beta cell dysfunction (Aggarwal et al, 2012) or by 99 
beta cell apoptosis induced by pancreatic stellate cells (Kikuta et al, 2013). Thus, diabetes is both 100 
causal and consequential to pancreatic cancer, the latter offering a window for screening, early 101 
tumor detection and therapy (Jenkinson et al, 2015).  102 
The survival of diabetic cancer patients compared with normoglycemic individuals across all cancer 103 
types seems to be less with risk ratios of around 1.4 (Barone et al, 2008; van de Poll-Franse et al, 104 
2007), but not for pancreatic cancer, possibly because of the limited cohort size (Park et al, 2006). 105 
Analysis of diabetes as covariate on survival outcome in advanced pancreatic is difficult due to the 106 
large number of variables and the very short survival. Preoperative diabetes found in 275 (56.3%) of 107 
488 patients with pancreatic cancer that had resection also did not influence survival although tumor 108 
size was significantly larger (mean=36 mm) compared to the non-diabetics (mean=33 mm) (Hart et 109 
al, 2014). In another study, 93 (45.4%) of 209 patients with pancreatic cancer and preoperative 110 
diabetes had a median survival of 15 months, which was less compared to 17 months in non-111 
diabetics with a hazard ratio of 1.55 (Chu et al, 2010). The risk of survival was even less in new onset 112 
diabetics (<2 years duration) compared to the longstanding diabetics with a hazard ratio of 1.75 (Chu 113 
et al, 2010). Diabetics also had a larger tumor size (mean = 38 mm) compared to non-diabetics 114 
(mean= 32 mm).  115 
 116 
Thus, the prognostic effect of diabetes mellitus in patients with pancreatic cancer is uncertain. The 117 
purpose of this study was to analyze the prognostic effect of clinically revealed diabetes on long term 118 
survival in pancreatic cancer patients following resection and adjuvant chemotherapy from three 119 
randomized controlled trials of the European Study Group for Pancreatic Cancer (ESPAC) trials, 120 
namely ESPAC-1Plus, ESPAC-1, and ESPAC-3 (Neoptolemos et al, 2001; Neoptolemos et al, 2010; 121 
Neoptolemos et al, 2004; Neoptolemos et al, 2009). 122 
  123 
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METHODS  126 
Patients 127 
Patients with pancreatic ductal adenocarcinoma were identified from the ESPAC-1Plus, ESPAC-1 and 128 
ESPAC-3 trials (Neoptolemos et al, 2001; Neoptolemos et al, 2010; Neoptolemos et al, 2004; 129 
Neoptolemos et al, 2009). These were open label, international, randomized phase III studies.  In 130 
order to improve homogeneity patients randomized to receive chemotherapy only were selected for 131 
this analysis. Patients were excluded if they had been randomized to either chemoradiation or to 132 
observation. There were 541 patients randomized together in ESPAC-1Plus and ESPAC-1 of whom 133 
164 patients were randomized to chemotherapy alone. There were 25 (15%) of these 164 patients 134 
with diabetes. There were 941 patients with ductal adenocarcinoma randomized in ESPAC-3 to either 135 
of two adjuvant chemotherapy regimens. There were 232 (25%) of these 941 patients with diabetes. 136 
The diabetes mellitus status was prospectively obtained by the principal investigator at each of the 137 
referring sites according to the best available clinical evidence and guidelines at that time and site, 138 
and categorized as no diabetes, insulin-dependent or non-insulin dependent diabetes.  Glucose 139 
tolerance testing or fasting glucose measurements were not routinely carried out, and data regarding 140 
duration of diabetes were not recorded (Neoptolemos et al, 2001; Neoptolemos et al, 2010; 141 
Neoptolemos et al, 2004; Neoptolemos et al, 2009). 142 
 143 
Statistical Analysis 144 
Clinical characteristics were compared across diabetic groups using two-sided Mann-Whitney U 145 
statistics for continuous characteristics and the Chi-Squared test for categorical variables.  146 
Multivariable regression using logistic regression was used to assess the relationship between clinical 147 
characteristics and diabetic status.  The primary outcome of interest was overall survival measured as 148 
the time from surgery until death by any cause. Survival estimates are calculated using the method of 149 
Kaplan and Meier (Kaplan & Meier, 1958) and compared across biological groups using Log-Rank 150 
tests (Peto & Peto, 1972).  Median follow-up is calculated using the reverse Kaplan Meier approach 151 
Gelöscht: Diabetes mellitus was prospectively obtained by 152 
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(Schemper & Smith, 1996).  Multivariable analyses are carried out using Cox proportional hazards 154 
models (Cox, 1972) and are constructed using forward selection based on Akaike’s Information 155 
Criterion (AIC).  The effects for trial and country are both included as stratification factors.  Only 156 
covariated with a univariate significance of P<0.25 are considered for selection in the multivariable 157 
model. Assessment of maximum tumor size carried out using a log(x+1) transformation on 158 
continuous covariate. Proportional hazards assumptions are evaluated via assessment of Schoenfelds 159 
residuals (Schoenfeld, 1982). Further sensitivity analyses are carried out using a landmark method, 160 
excluding patients who died within 30, 60, and 90 days of randomisation.  All analyses were carried 161 
out using R (v 3.2.1) (R-Development-Core-Team, 2011) on an intention to treat basis, retaining 162 
patients in their randomized treatment groups and including protocol violators and ineligible 163 
patients.  A two-sided significance of P<0.05 was used throughout. 164 
 165 
RESULTS 166 
Clinical and Pathological Variables 167 
A total of 1105 patients were included in the analysis, 164 (15%) patients from the ESPAC-1 studies 168 
and 941 (85%) patients from the ESPAC-3 study. There were 25 (15%) and 232 (25%) diabetics 169 
respectively from these studies. Together there were 257 (23%) patients with clinically revealed 170 
diabetes mellitus and 848 (77%) who were non-diabetic at the point of randomization. Patient 171 
characteristics at baseline and univariate analyses are presented to identify patient characteristics 172 
associated with diabetes (Table 1).  Patients with diabetes were significantly older with a median 173 
(interquartile range) age of 65 (57-71) years versus 63 (56-69) years for non-diabetics (p=0.04), and 174 
had an increased median (interquartile range) weight at presentation of 72 (62, 80) kg versus 66 (58, 175 
75) kg for non-diabetics (p<0.001). Diabetic patients were also more likely to have concurrent 176 
medical conditions other than diabetes (64% versus 42%; p<0.001). 146 of 257 (57%) diabetic 177 
patients completed all six cycles of adjuvant therapy, which was not significantly different from the 178 
458 of 848 (54%) non diabetic patients (p=0.47). The mean (sd) maximum tumor size (MTS), was 179 
33.59 (20.64) mm in diabetic patients and 29.67 (14.53) mm in non-diabetic patients with 180 
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significantly larger tumors in diabetic patients (p=0.026, MTS compared on the log scale). Diabetic 189 
patients had proportionally larger resections in the form of total pancreatectomy (12%) compared to 190 
non-diabetics (1%; p<0.001) although the distribution of tumor location was not significantly 191 
different between diabetic and non-diabetic patients (p=0.216). There were no significant 192 
preoperative or postoperative differences between insulin dependent and non-insulin dependent 193 
patients. Multivariable analysis identified increased age and increased weight as clinical 194 
characteristics independently associated with pre-operative diabetes (Table 2). Further, increased 195 
maximum tumor size but also a lower proportion of positive lymph nodes, were independently 196 
associated with pre-operative diabetes. 197 
 198 
Overall Survival 199 
Eight hundred and sixty two patients (78%) died during the course of both trial sets.  The median 200 
(95% confidence interval) overall survival was 21.4 (20.2, 23.4) months.  The median (95% confidence 201 
interval) overall survival for non-diabetics was 22.3 (20.8 - 24.1) months compared to 18.8 (16.9 - 202 
22.1) months for diabetic patients.  Analysis of the overall survival by diabetic status obtained Χ2LR 203 
(1DF) = 1.39 (p=0.238). Multivariable model analysis for overall survival identified World Health 204 
Organization (WHO) performance status and smoking status as independent prognostic clinical 205 
indicators and resection margin status, tumor differentiation and lymph node involvement as 206 
independent prognostic pathological indicators (Table 3).  Following adjustment of other terms, 207 
diabetic status was significantly associated with survival, with diabetic patients having an increased 208 
risk of death (Hazard Ratio: 1.19 (95% confidence interval: 1.01, 1.40), p=0.034). The fitted effect of 209 
diabetic status is given in Figure 1.  Assessment of Schoenfeld residuals did not identify any 210 
prognostic factors, which may be associated with non-proportional hazards. 211 
 212 
Of the 257 patients who were diabetic, insulin status was missing in two patients. One hundred and 213 
forty four (56%) of these 255 patients were insulin-dependent and the remainder (n=111) were non-214 
insulin dependent received either oral antidiabetics or were controlled by diet alone. At least 13 215 
Gelöscht: unadjusted 216 
Gelöscht:  217 
Gelöscht:  (Figure 1).  218 
Gelöscht:  219 
British Journal of Cancer  19 July 2016 
Page 9 of 17 
 
Gelöscht: 19 July 201618 July 201604 July 2016
patients were receiving oral antidiabetic therapy (seven taking metformin) but specific information 220 
was not available for the remaining 98 non-insulin dependent diabetics. The median (95% confidence 221 
interval) overall survival estimates was 18.0 (16.5, 21.1) months for patients who used insulin and 222 
20.5 (16.0, 26.6) months for patients who did not use insulin. The unadjusted overall survival by 223 
diabetic status was not significant (Χ2LR (1DF) = 0.03, p=0.857).  The unadjusted overall survival for 224 
diabetics in those using insulin versus metformin versus other oral diabetic medication was not 225 
significant (Χ2LR (2DF) = 0.80, p=0.371). The median (95% confidence interval) overall survival estimates 226 
was 18.0 (16.5, 21.1) months for patients who used insulin (n=144) and 22.2 (20.7, 23.9) months for 227 
patients who were not diabetic or who were non-insulin dependent (n=959) (Χ2LR (1DF) = 0.4, p=0.527).   228 
In insulin-dependent diabetic patients the median (95% confidence interval) overall survival 229 
estimates with a maximum tumor diameter > 30mm was 17.0 (15.2-22.7) months compared to 18.5 230 
(15.9-26.1) months for patients a maximum tumor diameter < 30mm (Hazard ratio [95% confidence 231 
interval] =0.96 (0.65,1.4); p=0.823). In non-insulin diabetic dependent patients with a maximum 232 
tumor diameter > 30mm was 14.6 (9.51-21.9) months compared to 32.0 (22.11-41.4) months for 233 
patients a maximum tumor diameter < 30mm (Hazard ratio [95% confidence interval] =1.99 [1.30, 234 
3.03]; p<0.001).  The overall survival difference was significant (Χ2LR (3DF) = 10.37, p=0.016) (Figure 2). 235 
A multivariable analysis was carried out of factors independently associated with overall survival 236 
specifically in the 257 diabetic patients. Due to the interaction between insulin status and maximum 237 
tumor size, we included the latter as a nested effect within insulin status, allowing for separate 238 
hazard ratios for insulin dependent and non-dependent groups.  This showed that lymph node 239 
metastasis remained an independent prognostic factor (Table 4). There was also a significant effect 240 
of maximum tumor size for non-insulin dependent patients but not for patients who were insulin-241 
dependent. Landmark analyses, removing patients who died within the first 30, 60 and 90 days 242 
respectively showed that the magnitude and direction of all treatment effects remained consistent 243 
showing that the effects reported are not overly effected by early deaths.  Details are included in 244 
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supplementary table 1.  Further to this, assessment of Schoenfeld residuals did not identify any 247 




The present study shows that diabetes mellitus is associated with increased tumor size and a small 252 
but significant increased overall risk of death with a hazard ratio of 1.19. There was a significant 253 
effect of maximum tumor size on survival for non-insulin dependent but not for insulin dependent 254 
diabetic patients. Two specific smaller studies also showed increased tumor size with diabetes with 255 
only one of these found a worse prognosis for diabetic patients following tumor resection (Chu et al, 256 
2010; Hart et al, 2014).  A meta-analysis of retrospective studies demonstrated worse prognosis in 257 
diabetic patients following resection with a hazard ratio of 1.32 (Walter et al, 2014).  258 
 259 
Taken together, there is now solid evidence that the diabetic state at the time of resection influences 260 
outcome. There are several concepts on how diabetes mellitus might impact on prognosis of 261 
pancreatic cancer patients. Patients with long standing type II diabetes exhibit insulin resistance and 262 
hypersecretion of insulin (Fisher et al, 1996; Li, 2012). In addition, elevated insulin levels result in 263 
increased bioavailability of IGFs and pancreatic cancer cells highly express high-affinity insulin and 264 
IGF receptors (Li, 2012). Insulin has been shown to act as a mitogen for pancreatic cancer cells (Ding 265 
et al, 2000; Fisher et al, 1996), and IGF-1 -besides its mitogenic effects, induces angiogenesis and 266 
increases invasion and blocks apoptosis of pancreatic cancer cells, thereby promoting tumor growth 267 
(Li, 2012). In line with this hypothesis, this and two other mentioned studies (Chu et al, 2010; Hart et 268 
al, 2014) have shown that diabetic patients have larger tumors at the time of resection. The present 269 
study has also demonstrated that the effects of diabetes on outcome were independent from tumor 270 
size, suggesting that other mechanisms are responsible for the worse prognosis of diabetic patients. 271 
It is conceivable that in the adjuvant setting, hyperinsulinemia supports growth of occult pancreatic 272 
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cancer cells, resulting in worsened prognosis. This might further be augmented by related obesity, 282 
leading to enhanced oxidative stress and inflammatory responses (Li, 2012). Indeed, the median 283 
weight of diabetic patients was significantly higher than of non-diabetic patients in the present 284 
analysis.  285 
 286 
The association between diabetes and tumor size has been substantiated from three large trials. 287 
Here, we show in addition, that in the group of diabetic patients, tumor size was an important 288 
prognostic indicator in non-insulin dependent, but not in insulin dependent patients. This suggests 289 
that in non-insulin dependent diabetes mellitus, tumor size has a predominant effect on prognosis 290 
whereas insulin dependent diabetes mellitus has a stronger, likely systemic effect on survival. There 291 
is evidence that therapies that increase insulin levels such as exogenous insulin or sulfonylurea could 292 
increase cancer risk. Therapies that decrease insulin levels by decreasing insulin resistance such as 293 
metformin, which also inhibits mTOR activity (Gong et al, 2014), would decrease the risk. Long 294 
duration (>15 years) of oral antidiabetics is associated with a decreased pancreatic cancer risk (OR 295 
0.31), whereas insulin use (<5 years) is associated with increased cancer risk (OR 5.6) (Bosetti et al, 296 
2014). A case control study has shown that diabetic patients on metformin had a significantly 297 
reduced risk of pancreatic cancer compared to patients not on metformin. In contrast, patients on 298 
insulin or insulin secretagogues had a significantly higher risk (Li et al, 2009), whilst a meta-analysis 299 
showed a reduced pancreatic cancer risk for patients on metformin but not sulfonylurea (Soranna et 300 
al, 2012). Another recent meta-analysis could not verify these associations between metformin or 301 
insulin and pancreatic cancer risk (Singh et al, 2013).  302 
 303 
A previous study has shown that the effect on survival was especially pronounced for recent onset 304 
diabetes (Chu et al, 2010). Tumors that induce diabetes might constitute a more aggressive subtype. 305 
Alternatively, symptoms of diabetes may mask symptoms of a developing tumor and contribute to 306 
delayed diagnosis. Our data on this aspect are conflicting, in as much as tumors of diabetic patients 307 
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were significantly larger, but had significantly less lymph node involvement and did not display 312 
differences in tumor differentiation. Furthermore, diabetic patients might have been treated less 313 
aggressively than non-diabetic patients, as it has been shown for other tumor entities (van de Poll-314 
Franse et al, 2007), although there was no difference in surgery and adjuvant therapy (including 315 
completion of therapy) in our series. On the other hand, it is also conceivable that cancer-induced 316 
diabetes results in earlier diagnosis, and thus in potentially better outcome. It could be speculated 317 
that all of these effects might play a role and that our data reflect the sum of these effects.   318 
 319 
This study relied on clinical data collected in prospectively randomized controlled trials of patients 320 
with histological proven ductal adenocarcinoma involving a total of 1105 patients of whom 257 (23%) 321 
were diabetic (Neoptolemos et al, 2001; Neoptolemos et al, 2010; Neoptolemos et al, 2004; 322 
Neoptolemos et al, 2009). Diabetes mellitus status was determined by the principal investigator at 323 
each of the referring sites according to the best available clinical evidence and guidelines at that time 324 
and site. This is a limitation of the present study, as no clear definition or test was utilized. Diagnosis 325 
reflected actual clinical care at the different sites and under-diagnosis is a likely issue, as routine use 326 
of specific tests (e.g. glucose tolerance test) was not mandatory within the ESPAC study protocols. 327 
Thus, it is possible that some of the patients were actually diabetic, but had not been formally 328 
assessed prior to therapy.  329 
 330 
In conclusion, diabetic patients that undergo resection for pancreatic cancer and adjuvant therapy 331 
present with larger tumors and have a small but significantly higher risk of death than non-diabetic 332 
patients. There seem to be important differences in patients with pancreatic cancer between those 333 
with insulin and non-insulin dependent diabetes mellitus and from previous studies between those 334 
with new onset and established diabetes mellitus. Understanding the biological mechanisms behind 335 
these observations may offer new opportunities for diagnosis and therapy. 336 
  337 
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Figure legends: 339 
 340 
Figure 1: Fitted effect of diabetic status on overall survival in 1105 pancreatic cancer patients 341 
following resection and adjuvant chemotherapy. Yes: diabetic patients; No: non-diabetic patients 342 
 343 
Figure 2:  Overall survival analysis in diabetic patients stratified according to whether patients were 344 
insulin-dependent (Yes) versus non-insulin-dependent (No), and maximum tumor diameter > 30 mm 345 
versus < 30 mm.346 
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